Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2‐ advanced breast cancer: MONARCH 2 & 3 trials

Source : https://onlinelibrary.wiley.com/doi/10.1111/cas.14877

This post‐hoc analysis of MONARCH 2 and MONARCH 3 assesses the efficacy, safety, and pharmacokinetics (PK) of abemaciclib in combination with endocrine therapy (ET) in East Asian patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2‐negative (HER2‐) advanced breast cancer.